On December 25, Genecast Group announced a strategic partnership with Sequanta Technologies. By leveraging their complementary strengths in technology development and industrial resources, the two companies will collaborate across key areas including product R&D, companion diagnostic development, and CDx services for innovative drug development. This partnership aims to accelerate the clinical translation and broader application of precision oncology.

Genecast Group is a leading innovator in tumor molecular diagnostics in China, with over eleven years of deep engagement in the field of precision oncology. Leveraging high-throughput sequencing platforms, advanced bioinformatics algorithms, and integrated translational medicine research systems, The company has successfully developed and commercialized comprehensive precision diagnosis solutions covering more than twenty cancer types. Genecast Group’s product portfolio spans three core clinical areas - treatment guidance, prognosis prediction, and early screening – and supported by a reliable, regulatory-compliant, one-stop service system. Backed by strong R&D and efficient product registration capabilities, The company has obtained multiple medical device certifications, including approvals from China’s NMPA and the EU CE. These capability enable Genecast Group to deliver professional, high quality molecular diagnostic and personalized treatment support to hospitals and medical institutions worldwide.

As a leader in multi-omics services, Sequanta Technologies has expanded its service coverage from traditional genomics and transcriptomics to proteomics and microbiomics, and has developed integrated multi-omics analysis solutions. The company is at the forefront of tumor immunity as well as cell and gene therapy research, and is committed to providing comprehensive support for disease mechanism studies, target and biomarker discovery, and standardized testing. These services are delivered to pharmaceutical companies, biotechnology firms, and academic research institutions across preclinical, clinical trial, and post-marketing stages.

This collaboration is founded on the strong complementarity of resources and capabilities between the two companies. Bo Du, the founder and CEO of Genecast Group stated that genetic testing, as an emerging technology in the medical field, brings new hope for the personalized treatment and serves as a cornerstone of precision medicine. Sequanta Technologies is a leading provider of NGS-based clinical trial services for pharmaceutical companies in China, serving both domestic and multinational clients. Genecast Group’ robust capabilities in genetic testing will provide solid support for the development of precision oncology diagnostic products. In addition, Genecast’s extensive clinical data and long-established expertise in mining and algorithm development will integrate seamlessly with Sequanta Technologies’ broad pharmaceutical service network. Together, this partnership is expected to significantly enhance the efficiency and accuracy of clinical validation, further accelerating the innovative application of companion diagnostics in novel drug development. The strategic collaboration between Genecast Group and Sequanta Technologies represents a highly synergistic and mutually reinforcing alliance, maximizing the integration of their respective strengths.

Lele Sun, Founder and CEO of Sequanta Technologies, stated that Sequanta Technologies has been deeply engaged in the pharmaceutical services sector for many years. By delivering flexible, customized multi-omics solutions while maintaining consistently high service standard, the company has provided top-tier technical services to pharmaceutical companies and researchers across both domestic and international biopharmaceutical markets. These efforts have enabled Sequanta Technologies to build a strong customer base and extensive business network. As a leader in precision oncology diagnosis, Genecast Group has accumulated substantial clinical experience and expertise in IVD product registration. Its diagnostic products demonstrate strong clinical performance, making them well suited to support pharmaceutical R&D and commercialization across all stages. This strategic collaboration represents a complementary and mutually beneficial integration of strengths. Together, the two companies will develop an integrated solution encompassing "discovery, clinical validation and translation, and parallel regulatory registration," seamlessly connecting biomarker discovery and patient stratification with companion diagnostic approval, and ultimately accelerating the development of innovative therapies.

Companion diagnostics are a critical driver of the innovation in drug development, and continued breakthroughs in gene sequencing technologies are opening broader horizons for the life sciences. Through this partnership, Genecast Group and Sequanta Technologies are integrating their respective strengths in diagnostic development and pharmaceutical services to build a more systematic service framework, addressing the industry's urgent need for closer synergy between precision diagnostics and drug development. Looking ahead, both parties will use this collaboration as a foundation to establish a new paradigm of synergy guided by a global perspective and integrated strategies. They will deepen cooperation across research and development, technological support, and service systems, while also exploring expanded collaboration in areas such as overseas pharmaceutical services and international market expansion. Together, these efforts will drive innovation, and high-quality development across the global pharmaceutical industry, bringing new hope to patients worldwide.